{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:32:53Z","timestamp":1790659973468,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11060-025-05251-2","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:31:59Z","timestamp":1761906719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Neurotoxicity in central nervous system tumors treated with CAR T cell therapy: a review"],"prefix":"10.1007","volume":"176","author":[{"given":"Jasia","family":"Mahdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane A.","family":"Gust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Vitanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Monje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Ronsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"issue":"5","key":"5251_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J et al (2018 Feb 1) Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med 378(5):439\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa1709866","journal-title":"N Engl J Med"},{"issue":"1","key":"5251_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS et al (2019 Jan 3) Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med 380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"issue":"10","key":"5251_CR3","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.Cd-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL (2018 Oct) Tumor antigen escape from CAR T-cell therapy. Cancer Discov 8(10):1219\u20131226. https:\/\/doi.org\/10.1158\/2159-8290.Cd-18-0442","journal-title":"Cancer Discov"},{"key":"5251_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","volume":"68","author":"K Newick","year":"2017","unstructured":"Newick K, O\u2019Brien S, Moon E, Albelda SM (2017 Jan 14) CAR T cell therapy for solid tumors. Annu Rev Med 68:139\u2013152. https:\/\/doi.org\/10.1146\/annurev-med-062315-120245","journal-title":"Annu. Rev. Med"},{"issue":"12 Suppl 2","key":"5251_CR5","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","volume":"23","author":"QT Ostrom","year":"2021","unstructured":"Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2021 Oct 5) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro Oncol 23(12 Suppl 2):iii1\u2013iii105. https:\/\/doi.org\/10.1093\/neuonc\/noab200","journal-title":"Neuro Oncol"},{"issue":"8","key":"5251_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11940-019-0577-y","volume":"21","author":"NA Vitanza","year":"2019","unstructured":"Vitanza NA, Monje M (2019 Jul 10) Diffuse intrinsic pontine glioma: from diagnosis to next-generation clinical trials. Curr Treat Options Neurol 21(8):37. https:\/\/doi.org\/10.1007\/s11940-019-0577-y","journal-title":"Curr Treat Options Neurol"},{"key":"5251_CR7","doi-asserted-by":"crossref","unstructured":"Song K-W, Issa S, Batchelor T (2021) Primary central nervous system lymphoma: epidemiology and clinical presentation. Annals of Lymphoma, 5","DOI":"10.21037\/aol-20-50"},{"key":"5251_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3389\/fonc.2012.00205","volume":"2","author":"KE Warren","year":"2012","unstructured":"Warren KE (2012) Diffuse intrinsic pontine glioma: poised for progress. Front Oncol 2:205. https:\/\/doi.org\/10.3389\/fonc.2012.00205","journal-title":"Front Oncol"},{"issue":"5","key":"5251_CR9","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41591-020-0827-2","volume":"26","author":"LK Donovan","year":"2020","unstructured":"Donovan LK, Delaidelli A, Joseph SK et al (2020 May) Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med 26(5):720\u2013731. https:\/\/doi.org\/10.1038\/s41591-020-0827-2","journal-title":"Nat Med"},{"issue":"7903","key":"5251_CR10","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner RG, Ramakrishna S, Yeom KW et al (2022 Mar) GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603(7903):934\u2013941. https:\/\/doi.org\/10.1038\/s41586-022-04489-4","journal-title":"Nature"},{"issue":"1","key":"5251_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","volume":"26","author":"CE Brown","year":"2018","unstructured":"Brown CE, Aguilar B, Starr R et al (2018 Jan 3) Optimization of IL13R\u03b12-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against Glioblastoma. Mol Ther 26(1):31\u201344. https:\/\/doi.org\/10.1016\/j.ymthe.2017.10.002","journal-title":"Mol Ther"},{"issue":"21","key":"5251_CR12","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1200\/jco.2017.72.8089","volume":"35","author":"JH Sampson","year":"2017","unstructured":"Sampson JH, Maus MV, June CH (2017 Jul 20) Immunotherapy for brain tumors. J Clin Oncol 35(21):2450\u20132456. https:\/\/doi.org\/10.1200\/jco.2017.72.8089","journal-title":"J Clin Oncol"},{"issue":"6640","key":"5251_CR13","doi-asserted-by":"publisher","first-page":"eabo7649","DOI":"10.1126\/science.abo7649","volume":"380","author":"G Castellani","year":"2023","unstructured":"Castellani G, Croese T, Peralta Ramos JM, Schwartz M (2023 Apr 7) Transforming the understanding of brain immunity. Science 380(6640):eabo7649. https:\/\/doi.org\/10.1126\/science.abo7649","journal-title":"Science"},{"issue":"12","key":"5251_CR14","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.Cd-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA et al (2017 Dec) Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 7(12):1404\u20131419. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0698","journal-title":"Cancer Discov"},{"issue":"9","key":"5251_CR15","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/s41590-019-0433-y","volume":"20","author":"CM Jackson","year":"2019","unstructured":"Jackson CM, Choi J, Lim M (2019 Sep) Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat Immunol 20(9):1100\u20131109. https:\/\/doi.org\/10.1038\/s41590-019-0433-y","journal-title":"Nat Immunol"},{"issue":"4","key":"5251_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41417-025-00886-9","volume":"32","author":"A Ibrahim","year":"2025","unstructured":"Ibrahim A, Mohamady Farouk Abdalsalam N, Liang Z et al (2025 Apr) MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy. Cancer Gene Ther 32(4):371\u2013392. https:\/\/doi.org\/10.1038\/s41417-025-00886-9","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"5251_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.immuni.2014.08.015","volume":"41","author":"PT Thevenot","year":"2014","unstructured":"Thevenot PT, Sierra RA, Raber PL et al (2014 Sep 18) The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. Immunity 41(3):389\u2013401. https:\/\/doi.org\/10.1016\/j.immuni.2014.08.015","journal-title":"Immunity"},{"issue":"8","key":"5251_CR18","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41577-021-00508-z","volume":"21","author":"AF Salvador","year":"2021","unstructured":"Salvador AF, de Lima KA, Kipnis J (2021 Aug) Neuromodulation by the immune system: a focus on cytokines. Nat Rev Immunol 21(8):526\u2013541. https:\/\/doi.org\/10.1038\/s41577-021-00508-z","journal-title":"Nat Rev Immunol"},{"key":"5251_CR19","doi-asserted-by":"publisher","first-page":"990463","DOI":"10.3389\/fimmu.2022.990463","volume":"13","author":"H Sui","year":"2022","unstructured":"Sui H, Dongye S, Liu X et al (2022) Immunotherapy of targeting MDSCs in tumor microenvironment. Front Immunol 13:990463. https:\/\/doi.org\/10.3389\/fimmu.2022.990463","journal-title":"Front Immunol"},{"issue":"6","key":"5251_CR20","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.immuni.2017.06.007","volume":"46","author":"J Herz","year":"2017","unstructured":"Herz J, Filiano AJ, Wiltbank AT, Yogev N, Kipnis J (2017 Jun 20) Myeloid cells in the central nervous system. Immunity 46(6):943\u2013956. https:\/\/doi.org\/10.1016\/j.immuni.2017.06.007","journal-title":"Immunity"},{"issue":"11","key":"5251_CR21","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41571-021-00518-9","volume":"18","author":"M Ott","year":"2021","unstructured":"Ott M, Prins RM, Heimberger AB (2021 Nov) The immune landscape of common CNS malignancies: implications for immunotherapy. Nat Rev Clin Oncol 18(11):729\u2013744. https:\/\/doi.org\/10.1038\/s41571-021-00518-9","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"5251_CR22","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/nm.4397","volume":"23","author":"MW Salter","year":"2017","unstructured":"Salter MW, Stevens B (2017 Sep 8) Microglia emerge as central players in brain disease. Nat Med 23(9):1018\u20131027. https:\/\/doi.org\/10.1038\/nm.4397","journal-title":"Nat Med"},{"issue":"8","key":"5251_CR23","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.cell.2023.02.020","volume":"186","author":"DJ Kloosterman","year":"2023","unstructured":"Kloosterman DJ, Akkari L (2023 Apr 13) Macrophages at the interface of the co-evolving cancer ecosystem. Cell 186(8):1627\u20131651. https:\/\/doi.org\/10.1016\/j.cell.2023.02.020","journal-title":"Cell"},{"issue":"8046","key":"5251_CR24","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje M, Mahdi J, Majzner R et al (2025 Jan) Intravenous and intracranial GD2-CAR T cells for H3K27M(+) diffuse midline gliomas. Nature 637(8046):708\u2013715. https:\/\/doi.org\/10.1038\/s41586-024-08171-9","journal-title":"Nature"},{"issue":"5","key":"5251_CR25","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","volume":"24","author":"CW Mount","year":"2018","unstructured":"Mount CW, Majzner RG, Sundaresh S et al (2018 May) Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas. Nat Med 24(5):572\u2013579. https:\/\/doi.org\/10.1038\/s41591-018-0006-x","journal-title":"Nat Med"},{"issue":"8043","key":"5251_CR26","doi-asserted-by":"publisher","first-page":"E6","DOI":"10.1038\/s41586-024-08452-3","volume":"636","author":"M Monje","year":"2024","unstructured":"Monje M, Mahdi J, Majzner R et al (2024 Dec) Author correction: intravenous and intracranial GD2-CAR T cells for H3K27M(+) diffuse midline gliomas. Nature 636(8043):E6. https:\/\/doi.org\/10.1038\/s41586-024-08452-3","journal-title":"Nature"},{"issue":"23","key":"5251_CR27","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1200\/jco.23.02019","volume":"42","author":"FY Lin","year":"2024","unstructured":"Lin FY, Stuckert A, Tat C et al (2024 Aug 10) Phase I trial of GD2.CART cells augmented with constitutive interleukin-7 receptor for treatment of high-grade pediatric CNS tumors. J Clin Oncol 42(23):2769\u20132779. https:\/\/doi.org\/10.1200\/jco.23.02019","journal-title":"J Clin Oncol"},{"key":"5251_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf064","author":"J Gust","year":"2025","unstructured":"Gust J, Cole BL, Ronsley R et al (2025 Mar 12) Locoregional infusion of EGFR806-CAR T cells for recurrent or refractory pediatric CNS tumors: results of the completed BrainChild02 phase 1 clinical trial. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noaf064","journal-title":"Neuro Oncol"},{"issue":"9","key":"5251_CR29","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","volume":"27","author":"NA Vitanza","year":"2021","unstructured":"Vitanza NA, Johnson AJ, Wilson AL et al (2021 Sep) Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat Med 27(9):1544\u20131552. https:\/\/doi.org\/10.1038\/s41591-021-01404-8","journal-title":"Nat Med"},{"issue":"3","key":"5251_CR30","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","volume":"31","author":"NA Vitanza","year":"2025","unstructured":"Vitanza NA, Ronsley R, Choe M et al (2025 Mar) Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat Med 31(3):861\u2013868. https:\/\/doi.org\/10.1038\/s41591-024-03451-3","journal-title":"Nat Med"},{"issue":"4","key":"5251_CR31","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CE Brown","year":"2024","unstructured":"Brown CE, Hibbard JC, Alizadeh D et al (2024 Apr) Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med 30(4):1001\u20131012. https:\/\/doi.org\/10.1038\/s41591-024-02875-1","journal-title":"Nat Med"},{"issue":"5","key":"5251_CR32","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Logun M, Fraietta JA et al (2024 May) Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat Med 30(5):1320\u20131329. https:\/\/doi.org\/10.1038\/s41591-024-02893-z","journal-title":"Nat Med"},{"issue":"35","key":"5251_CR33","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/jco.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S et al (2021 Dec 10) Management of immune-related adverse events in patients treated with chimeric antigen receptor T-Cell therapy: ASCO guideline. J Clin Oncol 39(35):3978\u20133992. https:\/\/doi.org\/10.1200\/jco.21.01992","journal-title":"J Clin Oncol"},{"issue":"4","key":"5251_CR34","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019 Apr) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl 25(4):625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"5251_CR35","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi J, Dietrich J, Straathof K et al (2023 Apr) Tumor inflammation-associated neurotoxicity. Nat Med 29(4):803\u2013810. https:\/\/doi.org\/10.1038\/s41591-023-02276-w","journal-title":"Nat Med"},{"issue":"1","key":"5251_CR36","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","volume":"183","author":"KR Parker","year":"2020","unstructured":"Parker KR, Migliorini D, Perkey E et al (2020 Oct 1) Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell 183(1):126\u2013142.e17. https:\/\/doi.org\/10.1016\/j.cell.2020.08.022","journal-title":"Cell"},{"key":"5251_CR37","doi-asserted-by":"publisher","unstructured":"Faulhaber LD, Phuong AQ, Hartsuyker KJ et al (2021) Brain capillary obstruction during neurotoxicity in a mouse model of anti-CD19 chimeric antigen receptor T-cell therapy. Brain Commun 4(1). https:\/\/doi.org\/10.1093\/braincomms\/fcab309","DOI":"10.1093\/braincomms\/fcab309"},{"issue":"8","key":"5251_CR38","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/s43018-024-00764-7","volume":"5","author":"JM Vinnakota","year":"2024","unstructured":"Vinnakota JM, Biavasco F, Schwabenland M et al (2024 Aug) Targeting TGF\u03b2-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome. Nat Cancer 5(8):1227\u20131249. https:\/\/doi.org\/10.1038\/s43018-024-00764-7","journal-title":"Nat Cancer"},{"issue":"8","key":"5251_CR39","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.Cd-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D et al (2018 Aug) Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 8(8):958\u2013971. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-1319","journal-title":"Cancer Discov"},{"issue":"3","key":"5251_CR40","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1097\/CCM.0b013e3182a66b76","volume":"42","author":"C Traube","year":"2014","unstructured":"Traube C, Silver G, Kearney J et al (2014 Mar) Cornell assessment of pediatric delirium: a valid, rapid, observational tool for screening delirium in the PICU*. Crit Care Med 42(3):656\u2013663. https:\/\/doi.org\/10.1097\/CCM.0b013e3182a66b76","journal-title":"Crit Care Med"},{"issue":"2","key":"5251_CR41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.hemonc.2020.09.004","volume":"14","author":"M Melody","year":"2021","unstructured":"Melody M, Rahman ZA, Saunders H et al (2021 Jun) C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel. Hematol Oncol STEM Cell Ther 14(2):141\u2013146. https:\/\/doi.org\/10.1016\/j.hemonc.2020.09.004","journal-title":"Hematol Oncol STEM Cell Ther"},{"issue":"1","key":"5251_CR42","doi-asserted-by":"publisher","first-page":"20011","DOI":"10.1038\/s41598-022-24010-1","volume":"12","author":"DK Jones","year":"2022","unstructured":"Jones DK, Eckhardt CA, Sun H et al (2022 Nov 21) EEG-based grading of immune effector cell-associated neurotoxicity syndrome. Sci Rep 12(1):20011. https:\/\/doi.org\/10.1038\/s41598-022-24010-1","journal-title":"Sci Rep"},{"issue":"7","key":"5251_CR43","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/jnci\/djz017","volume":"111","author":"BD Hunter","year":"2019","unstructured":"Hunter BD, Jacobson CA (2019 Jul 1) CAR T-Cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions. J Natl Cancer Inst 111(7):646\u2013654. https:\/\/doi.org\/10.1093\/jnci\/djz017","journal-title":"J Natl Cancer Inst"},{"key":"5251_CR44","doi-asserted-by":"crossref","unstructured":"Ronsley RC, Wright M, Seidel J, Lee K, Wendler A, Annesley J, Jensen C, Park MC, Vitanza JR, Gust NA, J (2025) Tumor inflammation-associated neurotoxicity in children with diffuse intrinsic pontine glioma receiving B7-H3-targeting CAR T cells on brainchild-03. Neurooncol Pract","DOI":"10.1093\/nop\/npaf080"},{"key":"5251_CR45","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028964","author":"LD Kaulen","year":"2025","unstructured":"Kaulen LD, Martinez-Lage MAbramson JS et al (2025) Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy. Blood. https:\/\/doi.org\/10.1182\/blood.2025028964","journal-title":"Blood"},{"issue":"7","key":"5251_CR46","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A et al (2020 Jul 1) Effect of Nivolumab vs Bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol 6(7):1003\u20131010. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1024","journal-title":"JAMA Oncol"},{"issue":"8","key":"5251_CR47","doi-asserted-by":"publisher","first-page":"521","DOI":"10.18632\/aging.100797","volume":"7","author":"L Min","year":"2015","unstructured":"Min L, Hodi FS, Kaiser UB (2015 Aug) Corticosteroids and immune checkpoint blockade. Aging (albany NY) 7(8):521\u2013522. https:\/\/doi.org\/10.18632\/aging.100797","journal-title":"Aging (albany NY)"},{"issue":"2","key":"5251_CR48","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M (2022 Feb) Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 22(2):85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6","journal-title":"Nat Rev Immunol"},{"issue":"14","key":"5251_CR49","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/blood.2023020571","volume":"142","author":"P Karschnia","year":"2023","unstructured":"Karschnia P, Miller KC, Yee AJ et al (2023 Oct 5) Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood 142(14):1243\u20131248. https:\/\/doi.org\/10.1182\/blood.2023020571","journal-title":"Blood"},{"issue":"14","key":"5251_CR50","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood.2023021429","volume":"142","author":"CE Graham","year":"2023","unstructured":"Graham CE, Lee WH, Wiggin HR et al (2023 Oct 5) Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood 142(14):1248\u20131252. https:\/\/doi.org\/10.1182\/blood.2023021429","journal-title":"Blood"},{"issue":"23","key":"5251_CR51","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1182\/blood.2024028172","volume":"145","author":"V Blumenberg","year":"2025","unstructured":"Blumenberg V, Puliafito BR, Graham CE et al (2025 Jun 5) Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment. Blood 145(23):2788\u20132793. https:\/\/doi.org\/10.1182\/blood.2024028172","journal-title":"Blood"},{"issue":"2","key":"5251_CR52","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3322\/caac.21258","volume":"65","author":"JS Wefel","year":"2015","unstructured":"Wefel JS, Kesler SR, Noll KR, Schagen SB (2015 Mar) Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin 65(2):123\u2013138. https:\/\/doi.org\/10.3322\/caac.21258","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"5251_CR53","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1158\/1078-0432.Ccr-11-2903","volume":"19","author":"D Greene-Schloesser","year":"2013","unstructured":"Greene-Schloesser D, Moore E, Robbins ME (2013 May 1) Molecular pathways: radiation-induced cognitive impairment. Clin Cancer Res 19(9):2294\u20132300. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-11-2903","journal-title":"Clin Cancer Res"},{"key":"5251_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.03.041","author":"AC Geraghty","year":"2025","unstructured":"Geraghty AC, Acosta-Alvarez L, Rotiroti MC et al (2025 May 7) Immunotherapy-related cognitive impairment after car T cell therapy in mice. Cell. https:\/\/doi.org\/10.1016\/j.cell.2025.03.041","journal-title":"Cell"},{"issue":"12","key":"5251_CR55","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1016\/j.cell.2025.03.041","volume":"188","author":"AC Geraghty","year":"2025","unstructured":"Geraghty AC, Acosta-Alvarez L, Rotiroti MC et al (2025 Jun 12) Immunotherapy-related cognitive impairment after car T cell therapy in mice. Cell 188(12):3238\u20133258.e25. https:\/\/doi.org\/10.1016\/j.cell.2025.03.041","journal-title":"Cell"},{"issue":"1\u20132","key":"5251_CR56","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cell.2018.10.049","volume":"176","author":"EM Gibson","year":"2019","unstructured":"Gibson EM, Nagaraja S, Ocampo A et al (2019 Jan 10) Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive impairment. Cell 176(1\u20132):43\u201355.e13. https:\/\/doi.org\/10.1016\/j.cell.2018.10.049","journal-title":"Cell"},{"issue":"1","key":"5251_CR57","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","volume":"26","author":"J Ruark","year":"2020","unstructured":"Ruark J, Mullane E, Cleary N et al (2020 Jan) Patient-reported neuropsychiatric outcomes of long-Term survivors after chimeric antigen receptor T cell therapy. Biol Blood Marrow Transpl 26(1):34\u201343. https:\/\/doi.org\/10.1016\/j.bbmt.2019.09.037","journal-title":"Biol Blood Marrow Transpl"},{"key":"5251_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08171-9","author":"M Monje","year":"2024","unstructured":"Monje M, Mahdi J, Majzner R et al (2024 Nov 13) Intravenous and intracranial GD2-CAR T cells for H3K27M(+) diffuse midline gliomas. Nature. https:\/\/doi.org\/10.1038\/s41586-024-08171-9","journal-title":"Nature"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05251-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05251-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05251-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:35:08Z","timestamp":1767702908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05251-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5251"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05251-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicabile, invited review article. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable, invited review article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate declaration"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics declaration"}},{"value":"Journal of Neuro-Oncology.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Invited review"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}